UCB - Operating Expenses


UCB reported EUR2.96B in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Alcon AG USD 2.41B 123M Dec/2025
Almirall EUR 517.4M 32K Dec/2025
Amarin USD 51.48M 113K Dec/2025
argenx SE USD 914.57M 137.58M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bayer EUR 10.33B 126M Dec/2025
Galapagos EUR 120.26M 7.43M Dec/2025
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
GRIFOLS EUR 1.71B 193M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.78B 669M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Orion EUR 367.1M 64.9M Dec/2025
Recordati EUR 384.01M 82.67M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.96B 196M Dec/2025
Unibail Rodamco EUR 646.6M 25.4M Dec/2025